Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive

Nature Reviews Endocrinology

Volumn 9, Issue 2, 2013, Pages 67-68

  Holman, Rury R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIABETIC MICROANGIOPATHY; DRUG DOSE INCREASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; KIDNEY DYSFUNCTION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; METFORMIN;

EID: 84872836127     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.243     Document Type: Review

References (10)

1. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-Analysis of 102 prospective studies. Lancet 375, 2215-2222 (2010).
2. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319-328 (2012).
3. Abraira, C. et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 18, 1113-1123 (1995).
4. Smith, U., Gale, E. A. Does diabetes therapy influence the risk of cancer? Diabetologia 52, 1699-1708 (2009).
5. Harrison, L. B., Adams-Huet, B., Raskin, P. & Lingvay, I. β-cell function and preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 35, 1406-1412 (2012).
6. Inzucchi, S. E. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 35, 1364-1379 (2012).
7. The George Washington University Biostatistics Center. The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) [online], http://www2.bsc.gwu.edu/bsc/oneproj.php?pkey=60 (2012).
8. Bailey, C. J., Turner, R. C. Metformin. N. Engl. J. Med. 334, 574-579 (1996).
9. National Institute for Health and Clinical Excellence. Clinical guideline 87: Type 2 diabetes-newer agents (partial update of CG66) [online], http://guidance.nice.org.uk/CG87 (2012).
10. Ekström, N. et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2, e001076 (2012).